Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
Chau, Ian, Peck-Radosavljevic, Markus, Borg, Christophe, Malfertheiner, Peter, Seitz, Jean Francois, Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Kudo, Masatoshi, Poon, Ronnie, Pastorelli, Davide, BТом:
81
Мова:
english
Журнал:
European Journal of Cancer
DOI:
10.1016/j.ejca.2017.05.001
Date:
August, 2017
Файл:
PDF, 562 KB
english, 2017
File converter
Більше результатів пошуку
More benefits 
